ApoA-I
Reactions involving ApoA-I
Every recorded step where this molecule takes part
-
consumed ABCA1 (cholesterol/phospholipid efflux transporter) Lipoprotein Metabolism (Exogenous and End… ST-0129
ApoA-I + phospholipid → nascent discoidal HDL
Showing all 1 reactions.
Recent literature
Europe PMC · fetched just now · sorted by publication date
-
1
Redefining intranasal brain delivery: from nasal entry to meaningful parenchymal and cellular exposure.
Kim Y, Yun CO, Yoon AR. · 2026-10-01
open access unreviewed -
2
Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy.
Rui M, Fang L, Jia M, Liang W, Li Y, Ruan Y, Feng C. · 2025-12-17
cited 1× open access unreviewed -
3
Edaravone attenuates carbonyl-stress-driven ApoA-I carboxymethylation and macrophage cholesterol-handling dysfunction in diabetic atherosclerosis.
Ma HC, Xu YX, Zhang ZR, Zhang LF, Zhou XF, Luo HY, Xiong NQ, Song KC, Pu LJ. · 2026-07-30
unreviewed -
4
Novel associations of Claudin gene variants with kidney stone disease.
Liu IY, Haverfield J, MacKenzie E, Dufresne L, Ryan AK, Engert JC, Gupta IR. · 2026-07-16
open access unreviewed -
5
Abetalipoproteinemia With a Novel Microsomal Triglyceride Transfer Protein Gene Mutation and Unique Oxidized Lipoprotein Levels.
Hamasaki M, Hara K, Kotani K. · 2026-09-04
open access unreviewed -
6
COPI Coatomer Regulates Several Steps of HDL Metabolism.
Panteloglou G, Zanoni P, Law CS, Woods B, Othman A, Yalcinkaya M, Norrelykke SF, Rzepiela AJ, Stoma S, Steble… · 2026-08-13
unreviewed -
7
HDL-associated proteins affecting CVD and systemic inflammation.
Delk SC, Reddy ST. · 2026-08-12
unreviewed -
8
Post‑translational modifications in atherosclerosis: Roles, mechanisms and therapeutic potential (Review).
Xu X, Ma F, Yu W. · 2026-07-31
open access unreviewed -
9
Structural Basis for the Pro-amyloidogenic Action and Ligand Binding of a Novel W72R Variant of Human Apolipoprotein A-I.
Prokaeva T, Jayaraman S, Klimtchuk ES, Libbey C, Mendelson L, Spencer B, Chen H, Van Le NH, Sanchez A, Kelleh… · 2026-06-24
unreviewed -
10
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
Sattar N, Gerstein HC, D'Alessio D, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Nauck MA… · 2026-10-01
cited 8× open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.